New U.S. Food and Drug Administration (FDA) regulations imposed upon the controversial diabetes drug Avandia will prohibit local retail pharmacies to carry the medication due to a confirmed risk for heart attack and other cardiovascular complications.
This motion applies to three anti-diabetes drugs manufactured by GlaxoSmithKline, Avandia, Avandamet and Avandaryl, that contain rosiglitazone - a drug that increases sensitivity to insulin and removes extra glucose from blood.

